share_log

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target

Benzinga ·  Sep 12 01:04  · Ratings

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment